Ferrarotto, Renata http://orcid.org/0000-0002-3561-215X
Sousa, Luana G.
Qing, Yun
Kaya, Diana
Stephen, Bettzy
Jain, Dipti
Bell, Diana
Pant, Shubham
Tsimberidou, Apostolia M.
Janku, Filip
Blumenschein, George
Glisson, Bonnie S.
Ahnert, Jordi Rodon
Piha-Paul, Sarina A.
Lee, J. Jack
Wong, Michael K.
Lu, Charles
Meric-Bernstam, Funda
Naing, Aung
Clinical trials referenced in this document:
Documents that mention this clinical trial
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors
https://doi.org/10.1136/jitc-2020-000665
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
https://doi.org/10.1136/jitc-2020-001752
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study (Pre-results)
https://doi.org/10.1136/jitc-2020-001532
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial
https://doi.org/10.1136/jitc-2022-004822
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
https://doi.org/10.1136/jitc-2021-003540
Phase 2 study of pembrolizumab in patients with advanced rare cancers
https://doi.org/10.1136/jitc-2019-000347
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
https://doi.org/10.1007/s12325-021-01807-6
Letter to the editor from Pant<i>et al</i>
https://doi.org/10.1136/jitc-2021-003991
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
https://doi.org/10.1136/jitc-2022-005809
Funding for this research was provided by:
National Cancer Institute (P30CA016672)
Merck Sharp and Dohme
University of Texas MD Anderson Cancer Center
Article History
Received: 19 April 2021
Accepted: 25 May 2021
First Online: 9 July 2021